Clinical trial · Observational
Development and Application of AI-Based Therapeutic Strategies for Esophageal Cancer Integrating Multimodal Imaging and Digital Pathology
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this clinical study is to conduct a multi-center, big data study to create a neural network decision model for predicting treatment efficacy and prognosis based on multi-modal, multi-temporal imaging features combined with tumor microenvironment scores. It will also use various model interpretation techniques to clarify the role and mechanism of key biomarkers or strongly associated biomarker groups in treatment efficacy and prognosis. Ultimately, it aims to achieve the research and application of AI treatment strategies combining multi-modal imaging and digital pathology to guide clinicians in the personalized treatment strategies for patients with esophageal squamous cell carcinoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Neoadjuvant Therapy | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Multimodal AI Esophageal Carcinoma Cohort Protocol
- description
- Efficacy and Prognosis of Different Treatment Modalities for Esophageal Squamous Cell Carcinoma
Primary outcomes (4)
- measure
- Pathological Complete Response (pCR) Rate
- timeFrame
- January 2025 - December 2027
- description
- The proportion of patients achieving pathological complete response (ypT0 ypN0) after neoadjuvant therapy.
- measure
- Overall Survival (OS)
- timeFrame
- January 2025 - December 2027
- description
- The time from treatment initiation to death from any cause.
- measure
- Event-Free Survival (EFS)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged 18-70 years; 2. Histologically confirmed esophageal carcinoma by biopsy; 3. No prior antitumor therapy received. Exclusion Criteria: 1. Contraindications to MRI examination; 2. Poor compliance with antitumor therapy; 3. Unwillingness to participate in the study; 4. Image quality inadequate for diagnostic requirements.
References
Publications (0)
Data not yet available